TIDMAGL
RNS Number : 2994Q
Angle PLC
11 September 2017
For immediate release 11 September 2017
ANGLE plc ("the Company")
ANGLE ANNOUNCES CO-MARKETING PARTNERSHIP WITH QIAGEN
Combines ANGLE's CTC harvesting technology with QIAGEN's
downstream analysis and bioinformatics capabilities for circulating
tumor cell research
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce it has established a co-marketing
agreement with QIAGEN, a world-leading provider of molecular
testing solutions with more than 500,000 customers in Molecular
Diagnostics (human healthcare), Applied Testing (forensics,
veterinary testing and food safety), Pharma (pharma and biotech
companies) and Academia (life sciences research).
The partnership will seek to leverage the advantages of
combining ANGLE's world leading Parsortix system for harvesting
circulating tumor cells (CTCs) with QIAGEN's liquid biopsy solution
portfolio which consists of dedicated NGS (next generation
sequencing), PCR (polymerase chain reaction), single cell analysis
products and bioinformatics capabilities. The initial focus will be
on prostate and breast cancer research applications.
The agreement entails both companies offering the other's
products to its customer base and follows an intensive evaluation
of Parsortix by QIAGEN identifying the advantages of the
system.
Michael Kazinski, QIAGEN's Senior Director Molecular Preanalytic
Technologies commented:
"ANGLE's Parsortix system is a unique, epitope-independent CTC
solution offering easy, automated processing of whole blood to
harvest all types of CTCs, including the clinically relevant
mesenchymal CTCs, for analysis. It complements very well with our
AdnaTest CTC portfolio, now allowing for both phenotypic and
molecular characterization of CTCs. The modular combination
abilities of this system with QIAGEN's liquid biopsy-based Sample
to Insight offering, including AdnaTest, our targeted RNAseq and
single cell solutions, along with our bioinformatics offering, will
allow scientists and clinical researchers to significantly advance
their research."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"We are delighted that Parsortix has been selected by QIAGEN as
their label-free CTC harvesting technology. We believe the ability
to offer customers a combination of Parsortix with validated and
reliable downstream analysis technologies from a world leader such
as QIAGEN facilitates key aspects of the sales cycle and we look
forward to working closely together. Partnering is a core part of
ANGLE's strategy to secure widespread adoption of Parsortix right
across the market leveraging the customer base and distribution
channels of established players."
QIAGEN is a world-leading provider of liquid biopsy solutions
for molecular testing from Sample to Insight. In 2015, QIAGEN
introduced the first regulated companion diagnostic assay based on
molecular biomarkers from circulating tumor DNA. QIAGEN has created
a wide range of strong standards for the processing of liquid
biopsy samples, including circulating cell free DNA, messenger RNA,
circulating tumor cells, exosomes and others. Many of the solutions
offer fully integrated and highly automated workflows spanning from
collection through to the purified nucleic acid. The QIAGEN
solutions are used in numerous diagnostic and research workflows
and represent gold standards in terms of performance. Such
solutions allow liquid biopsies to be easier and less expensive to
perform than tissue biopsies and they allow for significantly
improved sensitivity, specificity and robustness of liquid biopsies
which can be reliably repeated at regular intervals for monitoring
of disease progression.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes +44 (0) 203 705 9318
Nigel Birks +44 (0) 203 705 9316
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. Parsortix has a CE Mark for Europe and
FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
About QIAGEN www.qiagen.com
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharma and biotech companies) and Academia (life sciences
research). As of June 30, 2017, QIAGEN employed approximately 4,600
people in over 35 locations worldwide. Further information can be
found at http://www.qiagen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQBLFFDKFEBBE
(END) Dow Jones Newswires
September 11, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024